nature portfolio

Corresponding author(s):	Jan Budczies, Albrecht Stenzinger
Last updated by author(s):	05.07.2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_		4.0			
Ç :	トつ	1	เรt	- 1.	\sim
	lа		ואו	- 1	

n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection No software was used for data collection beyond the different pipelines described in the manuscript.

Data analysis

No custom algorithms or software central to the research was used. The code used to compare the results of the five participating institutions is available upon request to the corresponding authors.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

The sequencing data generated in the study are available from the European Genome-phenome Archive (https://www.ebi.ac.uk/ega/datasets) under the Accession Number EGAD00001011087.

Research involving human participants, their data, or biological material
Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation),

and sexual orientation and race, e	ethnicity and racism.			
Reporting on sex and gender	No sex or gender information was collected.			
Reporting on race, ethnicity, or other socially relevant groupings	No race, ethnicity, or social grouping information was utilized.			
Population characteristics	Cancer patients treated in Germany.			
Recruitment	NCT MASTER program.			
Ethics oversight	nics oversight Ethics Committee of the Medical Faculty of Heidelberg University			
Note that full information on the appr	roval of the study protocol must also be provided in the manuscript.			
Field-specific re	eporting			
Please select the one below that i	is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
∑ Life sciences ☐ E	Behavioural & social sciences			
For a reference copy of the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life sciences stu	udy design			
All studies must disclose on these	points even when the disclosure is negative.			
Sample size 30				
Data exclusions No data was ex	ta was excluded from the analyses.			
Replication 5 participating	5 participating institutions			
Randomization Samples were	Samples were not separated into groups, thus randomization was not neccessary.			
Blinding Samples were	Samples were not separated into groups, thus blinding was not neccessary.			
We require information from authors	pecific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experimental s	systems Methods			
n/a Involved in the study	n/a Involved in the study			
Antibodies	ChIP-seq			
Eukaryotic cell lines	Flow cytometry			
Palaeontology and archaeo Animals and other organisr				
Allimas and other organisms				
Dual use research of concern				
Plants				